Montelukast Paediatric Aurobindo Pharma (Malta)

Montelukast, the active ingredient in Montelukast Paediatric Aurobindo Pharma (Malta), is a leukotriene receptor antagonist presented as a pediatric oral formulation for oral use. It is employed to manage asthma, exercise‑induced bronchoconstriction and allergic rhinitis in children. GNH USA supplies Montelukast Paediatric Aurobindo Pharma (Malta) as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control inflammatory airway diseases. - Asthma: reduces frequency and severity of bronchospasm episodes in pediatric patients. - Allergic rhinitis: alleviates nasal congestion, sneezing and itchy eyes caused by seasonal allergens. - Exercise‑induced bronchoconstriction: prevents airway narrowing during physical activity in children.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache - Abdominal pain - Cough - Sore throat - Nausea - Diarrhoea

Serious or Rare Side Effects: - Allergic reactions such as rash, angioedema or anaphylaxis - Neuropsychiatric events including mood changes or suicidal thoughts - Hepatic enzyme elevation - Severe skin reactions like Stevens‑Johnson syndrome - Bronchospasm paradoxically worsening - Hematologic abnormalities

When prescribing Montelukast, clinicians should consider several safety measures. - Monitor liver function: obtain baseline hepatic enzymes and repeat if clinically indicated. - Assess neuropsychiatric status: watch for mood swings, anxiety or suicidal ideation. - Use caution in severe hepatic impairment: dose adjustment may be required. - Avoid in patients with known hypersensitivity to montelukast or any formulation component. - Adjust in renal impairment: limited data, monitor renal function. - Store below 25°C: keep in the original pack, protect from moisture.

Montelukast may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Phenobarbital: strong enzyme inducer that can lower montelukast plasma levels. - Rifampin: reduces exposure by inducing hepatic metabolism. - Ketoconazole: potent CYP3A4 inhibitor that may increase montelukast concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR, monitor coagulation parameters. - Beta‑agonists: additive bronchodilatory effect, observe for excessive tachycardia. - NSAIDs: may increase risk of hepatic enzyme elevation, check liver function periodically.